SCHEMBL23847802

SCHEMBL23847802

CC(SS)c1ccc2c(c1)OCC(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
MMP12 P39900 1/20 0.46
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
PARP1 P09874 1/20 0.43
DRD4 P21917 6/20 0.40
DRD3 P35462 6/20 0.40
DRD2 P14416 5/20 0.40
KDM5B Q9UGL1 1/20 0.40
KIF11 P52732 1/20 0.40
NSD2 O96028 1/20 0.40
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HTR1A P08908 1/20 0.38
CHRM5 P08912 1/20 0.38
ADRA2A P08913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8001478 0.84 MMP12 (0.51) KCNH2MMP12CYP11B1CYP11B2PDE3B
SCHEMBL15887342 0.78 KCNH2 (0.48) KCNH2MMP12CYP11B1CYP11B2PDE3B
SCHEMBL4150146 0.78 PTGS1 (0.55) KCNH2MMP12CYP11B1CYP11B2PDE3B
SCHEMBL18500452 0.77 PARP1 (0.51) KCNH2MMP12CYP11B1CYP11B2PDE3B
SCHEMBL4143414 0.76 LMNA (0.53) KCNH2MMP12PDE3BPDE3APARP1
SCHEMBL9706789 0.73 KCNH2 (0.45) KCNH2MMP12CYP11B1CYP11B2PDE3B
SCHEMBL24999115 0.72 MMP12 (0.60) MMP12PDE3BPDE3APARP1ALDH1A1
SCHEMBL23432581 0.72 KIF11 (0.54) MMP12CYP11B1CYP11B2PDE3BPDE3A
SCHEMBL2059233 0.72 MMP12 (0.51) MMP12CYP11B1CYP11B2PDE3BPDE3A
SCHEMBL3594625 0.72 MMP12 (0.51) MMP12CYP11B1CYP11B2PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292285-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS NUVATION BIO INC (US) 2021-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292285-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS ADORA2A, ADORA3, ADORA1 KCNH2 3141/4885MMP12 4333/4885CYP11B1 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.